Close Menu
Home › Biocartis, Covance Sign Commercialization Agreement for Idylla

Biocartis, Covance Sign Commercialization Agreement for Idylla

Apr 23, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis has announced that it has signed a commercialization agreement with Covance, the clinical research organization owned by Laboratory Corporation of America, to offer its Idylla platform and oncology assay menu to Covance's global customer base.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Molecular Diagnostics

  1. UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

  2. ACMG Suggests Docs Evaluate All Breast Cancer Patients for Genetic Risk Test Suitability

  3. Tempus Acquires Commercial Lab, Precision Medicine Services Provider Akesogen

  4. Universal Genetic Testing in Breast Cancer May Result in More Harm Than Good, Experts Worry

    Premium

  5. NIH Awards $102.5M for Antibacterial Resistance Research, Dx Development

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.